141 related articles for article (PubMed ID: 3293538)
1. [Experimental study on carboplatin toxicity--a comparison with cisplatin].
Suzuki K; Usami T; Sudoko H; Ohtawara Y; Tajima A; Kawabe K; Aso Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2153-8. PubMed ID: 3293538
[TBL] [Abstract][Full Text] [Related]
2. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
3. Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.
Dominguez MF; Macias RI; Izco-Basurko I; de La Fuente A; Pascual MJ; Criado JM; Monte MJ; Yajeya J; Marin JJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1106-12. PubMed ID: 11356935
[TBL] [Abstract][Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
5. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow.
Prajda N; Kralovánszky J; Gal F; Kiss F; Kerpel-Fronius S
In Vivo; 1989; 3(4):267-70. PubMed ID: 2519864
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin nephrotoxicity and platinum-metallothioneins: uptake and toxicity in proximal tubular cells from rat kidney.
Boogaard PJ; Mulder GJ; Nagelkerke JF
Contrib Nephrol; 1990; 83():208-12. PubMed ID: 2100713
[No Abstract] [Full Text] [Related]
8. [Pharmacokinetics of new cisplatin analogues in experimental animals].
Fujita H; Okamoto M; Takao A
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1366-72. PubMed ID: 2658824
[TBL] [Abstract][Full Text] [Related]
9. Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in mice.
Boughattas NA; Lévi F; Fournier C; Hecquet B; Lemaigre G; Roulon A; Mathé G; Reinberg A
J Pharmacol Exp Ther; 1990 Nov; 255(2):672-9. PubMed ID: 2243347
[TBL] [Abstract][Full Text] [Related]
10. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
11. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity.
Thomas JP; Lautermann J; Liedert B; Seiler F; Thomale J
Mol Pharmacol; 2006 Jul; 70(1):23-9. PubMed ID: 16569706
[TBL] [Abstract][Full Text] [Related]
12. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin.
Nonclercq D; Toubeau G; Laurent G; Tulkens PM; Heuson-Stiennon JA
Exp Mol Pathol; 1989 Oct; 51(2):123-40. PubMed ID: 2680578
[TBL] [Abstract][Full Text] [Related]
13. Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats.
Ohno S; Siddik ZH; Baba H; Stephens LC; Strebel FR; Wondergem J; Khokhar AR; Bull JM
Cancer Res; 1991 Jun; 51(11):2994-3000. PubMed ID: 2032236
[TBL] [Abstract][Full Text] [Related]
14. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat.
Yonezawa A; Masuda S; Nishihara K; Yano I; Katsura T; Inui K
Biochem Pharmacol; 2005 Dec; 70(12):1823-31. PubMed ID: 16242669
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells.
Micetich KC; Barnes D; Erickson LC
Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476
[TBL] [Abstract][Full Text] [Related]
16. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Knox RJ; Friedlos F; Lydall DA; Roberts JJ
Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077
[TBL] [Abstract][Full Text] [Related]
19. The immediate early genes, c-fos, c-jun and AP-1, are early markers of platinum analogue toxicity in human proximal tubular cell primary cultures.
Wainford RD; Weaver RJ; Hawksworth GM
Toxicol In Vitro; 2009 Aug; 23(5):780-8. PubMed ID: 19383537
[TBL] [Abstract][Full Text] [Related]
20. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]